Rekindling cancer vaccines

Article metrics

  • An Erratum to this article was published on 07 December 2016

Interest in cancer vaccines is being reignited by a greater understanding of tumor immunology and the potential of combining immunogens with new breakthrough immunotherapies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Stimulatory and inhibitory factors in the cancer-immunity cycle.
Figure 2: Somatic mutation burden by cancer.

Change history

  • 02 November 2016

    In the version of this article initially published, on p.1024, middle column, the quote, “We have ipilimumab....” should have read, “We have tremelimumab....” The error has been corrected in the HTML and PDF versions of the article.

References

  1. 1

    Schumacher, T.N. & Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).

  2. 2

    Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).

  3. 3

    Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387–1390 (2015).

  4. 4

    Bouchie, A. & DeFrancesco, L. Nature Biotechnology's academic spinouts of 2015. Nat. Biotechnol. 34, 484–492 (2016).

  5. 5

    Le, D.T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382–389 (2013).

  6. 6

    Lutz, E.R., Kinkead, H., Jaffee, E.M. & Zheng, L. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. OncoImmunology 3, e962401 (2014).

  7. 7

    Garde, D. Aduro slips after trial patient comes down with a dangerous infection. Fierce Biotech, 24 November http://www.fiercebiotech.com/r-d/aduro-slips-after-trial-patient-comes-down-a-dangerous-infection (2015).

  8. 8

    Feuerstein, A. Advaxis cancer immunotherapy on hold due to patient death. The Street, 6 October https://www.thestreet.com/story/13314660/1/advaxis-cancer-immunotherapy-on-hold-due-to-patient-death.html (2015).

  9. 9

    Jochems, C. et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol. Immunother. 63, 407–418 (2014).

  10. 10

    Chen, D.S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).

  11. 11

    Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

  12. 12

    Gulley, J.L. et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11, 3353–3362 (2005).

  13. 13

    Fong, L. et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J. Natl. Cancer Inst. 106, dju268 (2014).

  14. 14

    Sheikh, N. et al. Clonotypic diversification of intratumoral T cells following Sipuleucel-T treatment in prostate cancer subjects. Cancer Res. 76, 3711–3718 (2016).

  15. 15

    Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 6, 238ra70 (2014).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Branca, M. Rekindling cancer vaccines. Nat Biotechnol 34, 1019–1024 (2016) doi:10.1038/nbt.3690

Download citation

Further reading